Manifestações orais nas doenças inflamatórias intestinais: o que o cirurgião-dentista deve saber
DOI:
https://doi.org/10.22491/1983-7550-52-2-C1Palavras-chave:
Doença de Crohn, Doenças inflamatórias intestinais, Retocolite UlcerativaResumo
A carta ao editor “Manifestações orais nas doenças inflamatórias intestinais: o que o cirurgião-dentista deve saber” apresenta uma síntese atualizada sobre as lesões bucais associadas às doenças inflamatórias intestinais (DIIs) — principalmente Doença de Crohn (DC) e Retocolite Ulcerativa (RCU) — e destaca a importância do reconhecimento dessas alterações pelo cirurgião-dentista. O texto descreve que as DIIs são doenças crônicas de origem multifatorial, com manifestações que podem atingir todo o trato gastrointestinal e, frequentemente, a mucosa oral. As lesões orais podem preceder os sintomas intestinais e se classificam em específicas (como edema labial, ulcerações lineares e mucogengivite granular) e não específicas (como estomatite aftosa recorrente, pioestomatite vegetante e doença periodontal). Também aborda as alterações orais induzidas por medicamentos usados no tratamento das DIIs — como corticoides, tiopurinas, metotrexato e terapias biológicas — que podem causar mucosite, infecções oportunistas e reações liquenoides. Por fim, a carta ressalta o papel essencial do cirugião-dentista no diagnóstico precoce e na conduta terapêutica das manifestações orais, defendendo a integração entre odontologia e gastroenterologia para o manejo eficaz dessas doenças.
Referências
1. Lankarani KB, Sivandzadeh GR, Hassanpour S. Oral manifestation in inflammatory bowel disease: a review. World J Gastroenterol. 2013;19(46):8571-9.
2. Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(7):390-407.
3. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60(5):571-607.
4. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol. 1995;30(7):699-706.
5. Yasmin F, Najeeb H, Shaikh S, Hasanain M, Naeem U, Moeed A, et al. Novel drug delivery systems for inflammatory bowel disease. World J Gastroenterol. 2022;28(18):1922-33.
6. Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: A population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13(4):481-9.
7. Flynn S, Eisenstein S. Inflammatory Bowel Disease Presentation and Diagnosis. Surg Clin North Am. 2019;99(6):1051-62.
8. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review. Gastroenterology. 2012;142(1):46-54.
9. Quaresma AB, Kaplan GG, Kotze PG. The globalization of inflammatory bowel disease: the incidence and prevalence of inflammatory bowel disease in Brazil. Curr Opin Gastroenterol. 2019;35(4):259-64.
10. Gasparini RG, Sassaki LY, Saad-Hossne R. Inflammatory bowel disease epidemiology in São Paulo State, Brazil. Clin Exp Gastroenterol. 2018;11:423-9.
11. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427-34.
12. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007;117(3):514-21.
13. Adam H, Alqassas M, Saadah OI, Mosli M. Extraintestinal Manifestations of Inflammatory Bowel Disease in Middle Eastern Patients. J Epidemiol Glob Health. 2020;10(4):298-303.
14. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The Prevalence of Extraintestinal Diseases in Inflammatory Bowel Disease: A Population-Based Study: Am J Gastroenterol. 2001;96(4):1116-22.
15. Veauthier B, Hornecker JR. Crohn’s Disease: Diagnosis and Management. Am Fam Physician. 2018;98(11):661-9.
16. Ribaldone DG, Brigo S, Mangia M, Saracco GM, Astegiano M, Pellicano R. Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity. Medicines (Basel). 2020;7(6):33.
17. Lauritano D, Boccalari E, Stasio DD, Vella FD, Carinci F, Lucchese A, et al. Prevalence of Oral Lesions and Correlation with Intestinal Symptoms of Inflammatory Bowel Disease: A Systematic Review. Diagnostics. 2019;9(3):77.
18. Laranjeira N, Fonseca J, Meira T, Freitas J, Valido S, Leitão J. Oral mucosa lesions and oral symptoms in inflammatory bowel disease patients. Arq Gastroenterol. 2015;52(2):105-10.
19. Lourenço SV, Hussein TP, Bologna SB, Sipahi AM, Nico MMS. Oral manifestations of inflammatory bowel disease: a review based on the observation of six cases. J Eur Acad Dermatol Venereol. 2010;24(2):204-7.
20. Muhvić-Urek M, Tomac-Stojmenović M, Mijandrušić-Sinčić B. Oral pathology in inflammatory bowel disease. World J Gastroenterol. 2016;22(25):5655-67.
21. Gibson J, Wray D, Bagg J. Oral staphylococcal mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;89(2):171-6.
22. Fatahzadeh M, Schwartz RA, Kapila R, Rochford C. Orofacial Crohn’s disease: an oral enigma. Acta Dermatovenerol Croat. 2009;17(4):289-300.
23. Ribaldone DG, Brigo S, Mangia M, Saracco GM, Astegiano M, Pellicano R. Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity. Medicines (Basel). 2020;7(6):33.
24. Atarbashi-Moghadam S, Lotfi A, Atarbashi-Moghadam F. Pyostomatitis Vegetans: A Clue for Diagnosis of Silent Crohn’s Disease. J Clin Diagn Res. 2016;10(12):ZD12-3.
25. Lira-Junior R, Figueredo CM. Periodontal and inflammatory bowel diseases: Is there evidence of complex pathogenic interactions? World J Gastroenterol. 2016;22(35):7963-72.
26. Papageorgiou SN, Hagner M, Nogueira AVB, Franke A, Jäger A, Deschner J. Inflammatory bowel disease and oral health: systematic review and a meta-analysis. J Clin Periodontol. 2017;44(4):382-93.
27. Farrell RJ, Peppercorn MA, Fine SN, Michetti P. Mesalamine-associated thrombocytopenia. Am J Gastroenterol. 1999;94(8):2304-6.
28. Sandborn WJ. Steroid-dependent Crohn’s disease. Can J Gastroenterol. 2000;14(Suppl C):17C-22C.
29. Deeming GMJ, Collingwood J, Pemberton MN. Methotrexate and oral ulceration. Br Dent J. 2005;198(2):83-5.
30. Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J Crohns Colitis. 2020;14(1):4-22.
31. Stein RB, Hanauer SB. Comparative Tolerability of Treatments for Inflammatory Bowel Disease. Drug Saf. 2000;23(5):429-48.
32. Edwards D, Boritz E, Cowen EW, Brown RS. Erythema multiforme major following treatment with infliximab. Oral Surgery, Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2013;115(2):e36-40.
33. Salama M, Lawrance IC. Stevens-Johnson syndrome complicating adalimumab therapy in Crohn’s disease. World J Gastroenterol. 2009;15(35):4449-52.
34. Qiaoyu H, Ting L, Jiadi Y, Yanhui P, Qing L, Na L. Efficacy of photodynamic therapy in the treatment of oral candidiasis: a systematic review and meta-analysis. BMC Oral Health. 2023 Oct;23(1):802.
35. Al-Hallak MAG, Karkoutly M, Hsaian JA, Aljoujou AA. Effect of combined antimicrobial photodynamic therapy and photobiomodulation therapy in the management of recurrent herpes labialis: a randomized controlled trial. Sci Rep. 2025 May;15(1):16264.
36. Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443-68.
Downloads
Arquivos adicionais
Publicado
Edição
Seção
Licença
Copyright (c) 2025 Revista Naval de Odontologia
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
